2. Cytoskeleton Immunology/Inflammation
  3. Claudin Fc Receptor (FcR) Interleukin Related
  4. ZL-1211

ZL-1211 is an anti-CLDN18.2 monoclonal antibody. ZL-1211 exhibits enhanced binding affinity to CD16A. ZL-1211 induces ADCC-mediated cell lysis and triggers the production of IFNγ, TNFα and IL6. ZL-1211 promotes antibody-dependent cellular cytotoxicity. ZL-1211 exerts anti-tumor activity in a mouse xenograft model of gastric cancer. ZL-1211 can be used for the research of gastric cancer.

For research use only. We do not sell to patients.

ZL-1211

ZL-1211 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

ZL-1211 Related Antibodies

Top Publications Citing Use of Products

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

ZL-1211 is an anti-CLDN18.2 monoclonal antibody. ZL-1211 exhibits enhanced binding affinity to CD16A. ZL-1211 induces ADCC-mediated cell lysis and triggers the production of IFNγ, TNFα and IL6. ZL-1211 promotes antibody-dependent cellular cytotoxicity. ZL-1211 exerts anti-tumor activity in a mouse xenograft model of gastric cancer. ZL-1211 can be used for the research of gastric cancer[1].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target[1]

IL-6

 

In Vitro

ZL-1211 (1 h) specifically binds to CLDN18.2 on the surface of CHO cells and NUGC4 cells with overexpressed CLDN18.2[1].
ZL-1211 (serial dilution concentrations; 4-5 h) potently induces ADCC against CLDN18.2-overexpressing NUGC4-hCLDN18.2 cells via PBMC effector cells[1].
ZL-1211 (at serially diluted concentrations) potently induces ADCC effects against MIA-PaCa2-hCLDN18.2 cell clones with high, medium, and low CLDN18.2 expression via purified NK cells[1].
ZL-1211 (0.1 μg/mL; 20 min) potently induces complement-dependent cytotoxicity (CDC) against MIA-PaCa2-hCLDN18.2 cell clones with high and moderate CLDN18.2 expression via serum complement[1].
ZL-1211 (at serially diluted concentrations) potently induces antibody-dependent cell-mediated cytotoxicity (ADCC) against gastric cancer cell lines with high (SNU601), moderate (SNU620), and low (KATOIII) endogenous CLDN18.2 expression via purified NK cells at E:T ratios of 1:1 and 3:1. Its efficacy is significantly superior to that of clinical benchmark analogs, and it shows no activity against CLDN18.2-negative SNU5 cells[1].
ZL-1211 (0.01 μg/mL; 3 days) activates NK cells co-cultured with SNU601 gastric cancer cells, as evidenced by a significant increase in intracellular perforin levels compared with the control hIgG1[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ZL-1211 Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: CLDN18.2-overexpressing NUGC4-hCLDN18.2, peripheral blood mononuclear cell (PBMC) effector cells
Concentration: serially diluted concentrations (cytotoxicity assessment)
Incubation Time: 4-5 hours (incubation at 37°C)
Result: Induced robust ADCC-mediated tumor cell death, with greater potency than ZL-1211 wild-type Fc and the benchmark analog.

Cell Cytotoxicity Assay[1]

Cell Line: CLDN18.2-high, -medium, -low MIA-PaCa2-hCLDN18.2
Concentration: 0.1 μg/mL (CDC induction in high/medium clones)
Incubation Time: 20 minutes (pre-incubation at room temperature); 30 minutes (incubation at 37°C with complement)
Result: Induced CDC-mediated tumor cell death in CLDN18.2-high and -medium clones at 0.1 μg/mL, while the benchmark analog required a much higher concentration to induce CDC.
In Vivo

ZL-1211 (0.1-10 mg/kg; intraperitoneal injection; once weekly) exhibits significant dose-dependent antitumor efficacy against CLDN18.2 moderately expressing SNU620 gastric cancer in Balb/c nude mice, with significant tumor growth inhibition observed at doses as low as 0.1 mg/kg administered once weekly[1].
ZL-1211 (10 mg/kg; i.p.; once weekly) exhibits significant antitumor efficacy against CLDN18.2-low-expressing KATOIII gastric cancer tumors in Balb/c nude mice[1].
ZL-1211 (5 mg/kg; i.p.; once weekly) exerts NK cell-dependent antitumor efficacy against CLDN18.2-highly expressing SNU601 gastric cancer in Balb/c nude mice[1].
ZL-1211 (50 mg/kg; i.p.; three times per week) exerts dose-dependent anti-tumor efficacy against CLDN18.2-expressing gastric cancer PDX models in Balb/c nude mice, while enhancing NK cell infiltration into responsive tumors[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Balb/c nude mice (7-9 weeks old, female)[1]
Dosage: 0.1 mg/kg; 1 mg/kg; 10 mg/kg
Administration: i.p.; once weekly
Result: Suppressed SNU620 tumor growth at all tested doses.
Achieved significant tumor inhibition at 0.1 mg/kg, 1 mg/kg, and 10 mg/kg doses at day 42, with similar inhibition to benchmark antibody at 10 mg/kg despite having ~twice lower serum exposure than the benchmark.
Animal Model: Balb/c nude mice (7-9 weeks old, female)[1]
Dosage: 10 mg/kg
Administration: i.p.; once weekly
Result: Significantly suppressed KATOIII tumor growth, with smaller mean tumor volumes compared to the benchmark antibody at day 40.
Did not inhibit growth of CLDN18.2-negative SNU5 tumors.
Animal Model: Balb/c nude mice; NOD.SCID mice; NCG mice[1]
Dosage: 5 mg/kg
Administration: i.p.; once weekly
Result: Significantly suppressed SNU601 tumor growth in Balb/c nude mice, with mean tumor volumes ~50% lower than control at day 60.
Showed minimal to no tumor growth inhibition in NOD.SCID mice and NCG mice, correlating with tumor NK cell levels.
Animal Model: Balb/c nude mice[1]
Dosage: 50 mg/kg
Administration: i.p.; three times weekly
Result: Induced tumor growth inhibition (TGI) in 3 of 7 PDX models: GA0006 (TGI = 56.6%), GA6831 (TGI = 56.0%), and GA2419 (TGI = 40.3%).
No significant TGI was observed in CLDN18.2-negative PDX models.
Increased NK cell density significantly in treated tumors compared to control in the responder PDX group.
Gene ID

51208  [NCBI]

Accession
Target

CLDN18.2
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

ZL-1211 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ZL-1211ZL1211ZL 1211ClaudinFc Receptor (FcR)Interleukin RelatedFc ReceptorILantibody-dependent cellular cytotoxicityCLDN18.2NK cellsgastric cancerPBMC effector cellsMIA-PaCa2-hCLDN18.2 cellsNUGC4 cellsCD16AJurkat reporter cellsCHO cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
ZL-1211
Cat. No.:
HY-P992487
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.